This result has led to the accelerated approval of erdafitinib in 2019 by the US Food and Drug Administration (FDA) for locally advanced or metastatic urothelial carcinomas with FGFR2 and FGFR3 alterations. The gene discussed is FGFR3; the disease is urothelial carcinoma.